TL;DR
This study explores how immune checkpoint inhibitors may increase the risk of paraneoplastic syndrome in cancer patients.
Contribution
It provides real-world insights into the safety profile of immune checkpoint inhibitors.
Findings
Immune checkpoint inhibitors are linked to a higher risk of paraneoplastic syndrome.
The study uses large-scale real-world data to assess these risks.
Findings highlight the importance of monitoring patients for immune-related adverse events.
Abstract
The cover image is based on the article Pharmacovigilance Insights Into Immune Checkpoint Inhibitor‐Induced Risk of Paraneoplastic Syndrome: A Large‐Scale Real World Study by Bufu Tang et al., https://doi.org/10.1002/cns.70747.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCancer Immunotherapy and Biomarkers · Pharmacovigilance and Adverse Drug Reactions · Melanoma and MAPK Pathways